Reports
Sale
Middle East and Africa Generic Drugs Market Size, Share: By Therapy Area: Cardiovascular, Dermatology, Respiratory, Oncology, Rheumatology, Others; By Route of Administration: Oral, Injectables, Dermal/Topical, Inhalers, Others; By Distribution Channels: Hospital Pharmacy, Others; Regional Analysis; Supplier Landscape; 2024-2032
Middle East and Africa Generic Drugs Market Size
The Middle East and Africa generic drugs market was valued at USD 33 billion in 2023, driven by increasing healthcare needs and strategic partnerships in the region. The market is expected to grow at a CAGR of 7.42% during the forecast period of 2024-2032, with the values likely to rise from USD 35.4 billion in 2024 to USD 62.8 billion by 2032.
Middle East and Africa Generic Drugs Market Outlook
- The rising healthcare needs in Middle Eastern and African countries, due to the growing burden of chronic diseases and population growth are poised to augment the market demand.
- One of the major Middle East and Africa generic drugs market trends is the rise in strategic partnerships between local and international pharmaceutical companies. For instance, in September 2023, Cipla Limited signed an agreement to acquire Actor Pharma (Pty) Ltd, a South African over the counter (OTC) and generic medicines pharmaceutical company to gain entry into the South African market and strengthen its OTC drug offerings.
- Healthcare policies in the Middle East and North Africa region are increasingly focusing on reducing healthcare expenditure which is shifting the focus on improving the accessibility and uptake of affordable treatment options, thereby elevating the market value.
Middle East and Africa Generic Drugs Market Analysis
A generic drug contains the same active ingredients and offers similar clinical benefits as a brand-name medicine. They are generally marketed at lower prices (an estimated 80 to 85% less ) and thus serve as a cost-effective alternative to patent-protected medications. Healthcare policies in the Middle East and North Africa region are increasingly focusing on reducing healthcare expenditure which is shifting the focus on improving the accessibility and uptake of affordable treatment options, such as generic drugs. Further, the rising investment in healthcare infrastructure, such as hospitals and clinics, especially in under-developed areas, is expected to fuel the Middle East and Africa Generic Drugs market in the coming years.
The rising healthcare needs in the Middle Eastern and African countries, due to the growing burden of chronic diseases and population growth, are significantly contributing to the expansion of the global generic drugs market . The International Diabetes Federation states that diabetes prevalence in the region is projected to reach 136 million cases by 2045. Additionally, obesity is a severe problem in the Middle East and Africa, comprising 18 of the top 50 countries with high obesity rates globally. With the growing prevalence of chronic conditions (needing long-term medications), the Middle East and Africa Generic Drugs market demand is expected to witness a surge in the forecast period.
One of the major market trends is the rise in strategic partnerships between local and international pharmaceutical companies. For instance, in September 2023 , Cipla Limited, an Indian multinational pharmaceutical company signed an agreement to acquire Actor Pharma (Pty) Ltd, a South African-based pharmaceutical company specializing in over the counter (OTC) and generic medicines, at a deal worth USD 48.6 million . The acquisition was intended to enter the South African market and strengthen its OTC drug offerings. Such collaborations also allow the regional players to utilize advanced technology and expertise, which helps them to improve the manufacturing efficiency and quality of generic drugs. Thus, the increasing merger and acquisition activities are anticipated to boost the market share.
Middle East and Africa Generic Drugs Market Segmentation
The report offers a detailed analysis of the market based on the following segments:
| Market Breakup | Categories |
| Therapy Area | Cardiovascular, Dermatology, Respiratory, Oncology, Rheumatology, Others |
| Route of Administration | Oral, Injectables, Dermal/Topical, Inhalers, Others |
| Distribution Channels | Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others |
| Country | Saudi Arabia, Egypt, Others |
Leading Players in the Middle East and Africa Generic Drugs Market
The key features of the market report include patent analysis, grants analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
- Teva Pharmaceutical Industries Ltd
- Viatris Inc.
- AstraZeneca
- Baxter
- GSK plc
- Bausch + Lomb
- Novartis AG
- Sanofi
- Pfizer Inc.
- Fresenius SE & Co. KGaA
- Hikma Pharmaceuticals PLC
Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.
Key Highlights of the Report
| REPORT FEATURES | DETAILS |
| Base Year | 2023 |
| Historical Period | 2017-2023 |
| Forecast Period | 2024-2032 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Therapy Area |
|
| Breakup by Route of Administration |
|
| Breakup by Distribution Channels |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Supplier Landscape |
|
| Companies Covered |
|
Middle East and Africa Generic Drugs Market Report Snapshots
Middle East and Africa Generic Drugs Market Size
Middle East and Africa Generic Drugs Market Analysis
Middle East and Africa Generic Drugs Companies
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Middle East and Africa Generic Drugs Market Overview
3.1 Middle East and Africa Generic Drugs Market Historical Value (2017-2023)
3.2 Middle East and Africa Generic Drugs Market Forecast Value (2024-2032)
4 Middle East and Africa Generic Drugs Market Landscape*
4.1 Middle East and Africa Generic Drugs: Developers Landscape
4.1.1 Analysis by Year of Establishment
4.1.2 Analysis by Company Size
4.1.3 Analysis by Region
4.2 Middle East and Africa Generic Drugs: Product Landscape
4.2.1 Analysis by Therapy Area
4.2.2 Analysis by Route of Administration
4.2.3 Analysis by Distribution Channels
5 Middle East and Africa Generic Drugs Market Dynamics
5.1 Market Drivers and Constraints
5.2 SWOT Analysis
5.2.1 Strengths
5.2.2 Weaknesses
5.2.3 Opportunities
5.2.4 Threats
5.3 Porter’s Five Forces Model
5.3.1 Bargaining Power of Suppliers
5.3.2 Bargaining Power of Buyers
5.3.3 Threat of New Entrants
5.3.4 Threat of Substitutes
5.3.5 Degree of Rivalry
5.4 Key Demand Indicators
5.5 Key Price Indicators
5.6 Industry Events, Initiatives, and Trends
5.7 Value Chain Analysis
6 Middle East and Africa Generic Drugs Market Segmentation (2017-2032)
6.1 Middle East and Africa Generic Drugs Market (2017-2032) by Therapy Area
6.1.1 Market Overview
6.1.2 Cardiovascular
6.1.3 Dermatology
6.1.4 Respiratory
6.1.5 Oncology
6.1.6 Rheumatology
6.1.7 Others
6.2 Middle East and Africa Generic Drugs Market (2017-2032) by Route of Administration
6.2.1 Market Overview
6.2.2 Oral
6.2.3 Injectables
6.2.4 Dermal/Topical
6.2.5 Inhalers
6.2.6 Others
6.3 Middle East and Africa Generic Drugs Market (2017-2032) by Distribution Channels
6.3.1 Market Overview
6.3.2 Hospital Pharmacy
6.3.3 Retail Pharmacy
6.3.4 Online Pharmacy
6.3.5 Others
6.4 Middle East and Africa Generic Drugs Market (2017-2032) by Country
6.4.1 Market Overview
6.4.2 UAE
6.4.3 Saudi Arabia
6.4.4 Egypt
6.4.5 Others
7 UAE Generic Drugs Market Segmentation (2017-2032)
7.1 UAE Generic Drugs Market (2017-2032) by Therapy Area
7.1.1 Market Overview
7.1.2 Cardiovascular
7.1.3 Dermatology
7.1.4 Respiratory
7.1.5 Oncology
7.1.6 Rheumatology
7.1.7 Others
7.2 UAE Generic Drugs Market (2017-2032) by Route of Administration
7.2.1 Market Overview
7.2.2 Oral
7.2.3 Injectables
7.2.4 Dermal/Topical
7.2.5 Inhalers
7.2.6 Others
8 Saudi Arabia Generic Drugs Market Segmentation (2017-2032)
8.1 Saudi Arabia Generic Drugs Market (2017-2032) by Therapy Area
8.1.1 Market Overview
8.1.2 Cardiovascular
8.1.3 Dermatology
8.1.4 Respiratory
8.1.5 Oncology
8.1.6 Rheumatology
8.1.7 Others
8.2 Saudi Arabia Generic Drugs Market (2017-2032) by Route of Administration
8.2.1 Market Overview
8.2.2 Oral
8.2.3 Injectables
8.2.4 Dermal/Topical
8.2.5 Inhalers
8.2.6 Others
9 Egypt Generic Drugs Market Segmentation (2017-2032)
9.1 Egypt Generic Drugs Market (2017-2032) by Therapy Area
9.1.1 Market Overview
9.1.2 Cardiovascular
9.1.3 Dermatology
9.1.4 Respiratory
9.1.5 Oncology
9.1.6 Rheumatology
9.1.7 Others
9.2 Egypt Generic Drugs Market (2017-2032) by Route of Administration
9.2.1 Market Overview
9.2.2 Oral
9.2.3 Injectables
9.2.4 Dermal/Topical
9.2.5 Inhalers
9.2.6 Others
10 Regulatory Framework
10.1 Regulatory Overview
10.1.1 MOHAP UAE
10.1.2 SFDA Saudi Arabia
11 Patent Analysis
11.1 Analysis by Type of Patent
11.2 Analysis by Publication year
11.3 Analysis by Issuing Authority
11.4 Analysis by Patent Age
11.5 Analysis by CPC Analysis
11.6 Analysis by Patent Valuation
11.7 Analysis by Key Players
12 Grants Analysis
12.1 Analysis by Year
12.2 Analysis by Amount Awarded
12.3 Analysis by Issuing Authority
12.4 Analysis by Grant Housing Material
12.5 Analysis by Funding Institute
12.6 Analysis by Departments
12.7 Analysis by Recipient Organization
13 Funding and Investment Analysis
13.1 Analysis by Funding Instances
13.2 Analysis by Type of Funding
13.3 Analysis by Funding Amount
13.4 Analysis by Leading Players
13.5 Analysis by Leading Investors
13.6 Analysis by Geography
14 Partnership and Collaborations Analysis
14.1 Analysis by Partnership Instances
14.2 Analysis by Type of Partnership
14.3 Analysis by Leading Players
14.4 Analysis by Geography
15 Supplier Landscape
15.1 Market Share by Top 5 Companies
15.2 Teva Pharmaceutical Industries Ltd
15.2.1 Financial Analysis
15.2.2 Product Portfolio
15.2.3 Demographic Reach and Achievements
15.2.4 Mergers and Acquisitions
15.2.5 Certifications
15.3 Viatris Inc.
15.3.1 Financial Analysis
15.3.2 Product Portfolio
15.3.3 Demographic Reach and Achievements
15.3.4 Mergers and Acquisitions
15.3.5 Certifications
15.4 AstraZeneca
15.4.1 Financial Analysis
15.4.2 Product Portfolio
15.4.3 Demographic Reach and Achievements
15.4.4 Mergers and Acquisitions
15.4.5 Certifications
15.5 Baxter
15.5.1 Financial Analysis
15.5.2 Product Portfolio
15.5.3 Demographic Reach and Achievements
15.5.4 Mergers and Acquisitions
15.5.5 Certifications
15.6 GSK plc
15.6.1 Financial Analysis
15.6.2 Product Portfolio
15.6.3 Demographic Reach and Achievements
15.6.4 Mergers and Acquisitions
15.6.5 Certifications
15.7 Bausch + Lomb
15.7.1 Financial Analysis
15.7.2 Product Portfolio
15.7.3 Demographic Reach and Achievements
15.7.4 Mergers and Acquisitions
15.7.5 Certifications
15.8 Novartis AG
15.8.1 Financial Analysis
15.8.2 Product Portfolio
15.8.3 Demographic Reach and Achievements
15.8.4 Mergers and Acquisitions
15.8.5 Certifications
15.9 Sanofi
15.9.1 Financial Analysis
15.9.2 Product Portfolio
15.9.3 Demographic Reach and Achievements
15.9.4 Mergers and Acquisitions
15.9.5 Certifications
15.10 Pfizer Inc.
15.10.1 Financial Analysis
15.10.2 Product Portfolio
15.10.3 Demographic Reach and Achievements
15.10.4 Mergers and Acquisitions
15.10.5 Certifications
15.11 Fresenius SE & Co. KGaA
15.11.1 Financial Analysis
15.11.2 Product Portfolio
15.11.3 Demographic Reach and Achievements
15.11.4 Mergers and Acquisitions
15.11.5 Certifications
15.12 Hikma Pharmaceuticals PLC
15.12.1 Financial Analysis
15.12.2 Product Portfolio
15.12.3 Demographic Reach and Achievements
15.12.4 Mergers and Acquisitions
15.12.5 Certifications
16 Middle East and Africa Generic Drugs Market – Distribution Model (Additional Insight)
16.1 Overview
16.2 Potential Distributors
16.3 Key Parameters for Distribution Partner Assessment
17 Key Opinion Leaders (KOL) Insights (Additional Insight)
18 Company Competitiveness Analysis (Additional Insight)
18.1 Very Small Companies
18.2 Small Companies
18.3 Mid-Sized Companies
18.4 Large Companies
18.5 Very Large Companies
19 Payment Methods (Additional Insight)
19.1 Government Funded
19.2 Private Insurance
19.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.
* The coverage of the Market Landscape section depends on the data availability and may cover a minimum of 80% of the total market. The EMR team strives to make this section as comprehensive as possible.
Key Questions Answered in the Report
The market attained a value of about USD 33 billion in 2023 driven by increasing healthcare needs and strategic partnerships in the region.
The market is anticipated to grow at a CAGR of 7.42% during the forecast period of 2024-2032, likely to reach a market value of USD 62.8 billion by 2032.
The rising burden of chronic diseases and the growing population size are fuelling the demand for the market.
One of the significant trends in the market is the increasing merger and acquisition activities among key market players. To gain entry into the South African market and strengthen its OTC drug offerings, Cipla Limited signed an agreement to acquire Actor Pharma (Pty) Ltd, a South African OTC and generic medicines pharmaceutical company in September 2023.
Based on the therapy area, the market is segmented into cardiovascular, dermatology, respiratory, oncology, and rheumatology, among others.
By route of administration, the market is divided into oral, injectables, dermal/topical, and inhalers, among others.
The distribution channels of the market are hospital pharmacies, retail pharmacies, and online pharmacies, among others.
The market segmentation by countries includes UAE, Saudi Arabia, and Egypt, among others.
The key players in the market are Teva Pharmaceutical Industries Ltd., Viatris Inc., AstraZeneca, Baxter, GSK plc, Bausch + Lomb, Novartis AG, Sanofi, Pfizer Inc., Fresenius SE & Co. KGaA, and Hikma Pharmaceuticals PLC.
Purchase Options 10% off
Call us
Purchase Full Report
Mini Report
$ 2639
$2399
-
Selected Sections, One User
-
Printing Not Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Single User License
$ 4399
$3999
-
All Sections, One User
-
One Print Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Five User License
$ 5829
$5299
-
All Sections, Five Users
-
Five Prints Allowed
-
Email Delivery in PDF
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Corporate License
$ 6929
$6299
-
All Sections, Unlimited Users
-
Unlimited Prints Allowed
-
Email Delivery in PDF + Excel
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Any Question? Speak With An Analyst
View A Sample
Did You Miss Anything, Ask Now
Why Expert Market Research?
Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.
NEWSLETTER